Interpreting PFS Benefit and Quality-of-Life Data in SERENA-6

Carol Tweed, MD, unpacks how to interpret the progression-free survival benefit in the SERENA-6 trial, explaining that a second progression-free survival analysis, counted after patients on the standard arm crossed over to a subsequent therapy, still favored the camizestrant switch group. She argues this suggests benefit beyond simply receiving an active drug at some point, and that time to chemotherapy and quality-of-life measures, including reduced pain and better global health outcomes, matter more to patients than debates over which progression-free survival endpoint to use. Neil Iyengar, MD, describes his own shift from skepticism about lead-time bias to favoring the SERENA-6 paradigm, citing delayed time to chemotherapy and patient-reported outcome data as the most compelling reasons. Rebecca Shatsky, MD, adds that avoiding hair loss and intravenous infusions is especially meaningful for patients with breast cancer.